These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 23829664)

  • 1. Vaccine adjuvants: the future is bright. Interview by Jenaid Rees.
    Rappuoli R
    Expert Rev Vaccines; 2013 Jul; 12(7):727-9. PubMed ID: 23829664
    [No Abstract]   [Full Text] [Related]  

  • 2. Vaccine adjuvants: insights from industry. Interview by Jenaid Rees.
    Andréasson S
    Expert Rev Vaccines; 2013 Jul; 12(7):731-2. PubMed ID: 23885818
    [No Abstract]   [Full Text] [Related]  

  • 3. Vaccine adjuvants: in search of new paradigms. Interview by Jenaid Rees.
    Petrovsky N
    Expert Rev Vaccines; 2013 Jul; 12(7):723-6. PubMed ID: 23885817
    [No Abstract]   [Full Text] [Related]  

  • 4. Antibody and T-cell responses to a virosomal adjuvanted H9N2 avian influenza vaccine: impact of distinct additional adjuvants.
    Radosević K; Rodriguez A; Mintardjo R; Tax D; Bengtsson KL; Thompson C; Zambon M; Weverling GJ; Uytdehaag F; Goudsmit J
    Vaccine; 2008 Jul; 26(29-30):3640-6. PubMed ID: 18514980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term and cross-reactive immunogenicity of inactivated trivalent influenza vaccine in the elderly: MF59-adjuvanted vaccine versus unadjuvanted vaccine.
    Song JY; Cheong HJ; Noh JY; Seo YB; Choi WS; Cho GJ; Hwang TG; Kim WJ
    J Med Virol; 2013 Sep; 85(9):1591-7. PubMed ID: 23852684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvanted seasonal influenza vaccines and perpetual viral metamorphosis: the importance of cross-protection.
    Ansaldi F; Canepa P; Parodi V; Bacilieri S; Orsi A; Compagnino F; Icardi G; Durando P
    Vaccine; 2009 May; 27(25-26):3345-8. PubMed ID: 19200846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus.
    Khurana S; Chearwae W; Castellino F; Manischewitz J; King LR; Honorkiewicz A; Rock MT; Edwards KM; Del Giudice G; Rappuoli R; Golding H
    Sci Transl Med; 2010 Jan; 2(15):15ra5. PubMed ID: 20371470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influenza vaccine: development of a novel intranasal and subcutaneous recombinant adjuvant.
    Segura-Velázquez R; Cervantes J; Acosta E; Sánchez-Betancourt I; Villalobos N; Rodarte LF; Restelli M; Fragoso G; Sciutto E
    Vaccine; 2013 Aug; 31(37):4009-16. PubMed ID: 23746458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cross-reactive antibodies in middle-aged and elderly volunteers after MF59-adjuvanted subunit trivalent influenza vaccine against B viruses of the B/Victoria or B/Yamagata lineages.
    Camilloni B; Neri M; Lepri E; Iorio AM
    Vaccine; 2009 Jun; 27(31):4099-103. PubMed ID: 19410623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reply to letter to the editor.
    Van Buynder PG
    Vaccine; 2015 Mar; 33(10):1234. PubMed ID: 25620246
    [No Abstract]   [Full Text] [Related]  

  • 11. Induction of protective antibody response by MF59-adjuvanted 2009 pandemic A/H1N1v influenza vaccine in HIV-1-infected individuals.
    Kajaste-Rudnitski A; Galli L; Nozza S; Tambussi G; Di Pietro A; Pellicciotta G; Monti A; Mascagni P; Moro M; Vicenzi E
    AIDS; 2011 Jan; 25(2):177-83. PubMed ID: 21150561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Superior protection provided by a single dose of MF59-adjuvanted whole inactivated H5N1 influenza vaccine in type 1 diabetic mice.
    Wu J; Wang F; Fang F; Zhang W; Chang H; Zheng L; Chen Z
    Arch Virol; 2011 Mar; 156(3):387-95. PubMed ID: 21110049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant.
    Vesikari T; Pellegrini M; Karvonen A; Groth N; Borkowski A; O'Hagan DT; Podda A
    Pediatr Infect Dis J; 2009 Jul; 28(7):563-71. PubMed ID: 19561422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized clinical trial to identify the optimal antigen and MF59(®) adjuvant dose of a monovalent A/H1N1 pandemic influenza vaccine in healthy adult and elderly subjects.
    Hatz C; von Sonnenburg F; Casula D; Lattanzi M; Leroux-Roels G
    Vaccine; 2012 May; 30(23):3470-7. PubMed ID: 22446638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systems vaccinology informs influenza vaccine immunogenicity.
    García-Sastre A
    Proc Natl Acad Sci U S A; 2016 Feb; 113(7):1689-91. PubMed ID: 26842838
    [No Abstract]   [Full Text] [Related]  

  • 16. Influenza A/H1N1 MF59-adjuvanted vaccine in preterm and term children aged 6 to 23 months.
    Esposito S; Pugni L; Daleno C; Ronchi A; Valzano A; Serra D; Mosca F; Principi N
    Pediatrics; 2011 May; 127(5):e1161-8. PubMed ID: 21464195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. One dose of an MF59-adjuvanted pandemic A/H1N1 vaccine recruits pre-existing immune memory and induces the rapid rise of neutralizing antibodies.
    Faenzi E; Zedda L; Bardelli M; Spensieri F; Borgogni E; Volpini G; Buricchi F; Pasini FL; Capecchi PL; Montanaro F; Belli R; Lattanzi M; Piccirella S; Montomoli E; Ahmed SS; Rappuoli R; Del Giudice G; Finco O; Castellino F; Galli G
    Vaccine; 2012 Jun; 30(27):4086-94. PubMed ID: 22521851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody induction by virosomal, MF59-adjuvanted, or conventional influenza vaccines in the elderly.
    de Bruijn I; Meyer I; Gerez L; Nauta J; Giezeman K; Palache B
    Vaccine; 2007 Dec; 26(1):119-27. PubMed ID: 18063446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MF59-adjuvanted subunit influenza vaccine: an improved interpandemic influenza vaccine for vulnerable populations.
    Puig Barberà J; González Vidal D
    Expert Rev Vaccines; 2007 Oct; 6(5):659-65. PubMed ID: 17931147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1/2 clinical trial.
    Keitel W; Groth N; Lattanzi M; Praus M; Hilbert AK; Borkowski A; Tsai TF
    Vaccine; 2010 Jan; 28(3):840-8. PubMed ID: 19835829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.